| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | NSE - Starling Oncology, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | - | SEC Filings | ||
| 06.11. | Starling Oncology expects $650M-$660M revenue and $4M-$6M adjusted EBITDA in 2026 while targeting 100% capitated revenue growth in 2027 | 3 | Seeking Alpha | ||
| STARLING ONCOLOGY INSTITUTE Aktie jetzt für 0€ handeln | |||||
| 05.11. | Starling Oncology Q3 2026 Earnings Call Transcript | 2 | Benzinga.com | ||
| 05.11. | Starling Oncology, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 05.11. | The Oncology Institute GAAP EPS of -$0.14 misses by $0.09, revenue of $169.8M beats by $1.11M | 2 | Seeking Alpha | ||
| 05.11. | Starling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance | 1 | GlobeNewswire (USA) | ||
| 05.11. | Starling Oncology, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.10. | Needham raises Starling Oncology stock price target on growth outlook | 6 | Investing.com | ||
| 02.09. | Starling Oncology, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.08. | Starling Oncology, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 06.08. | Earnings Call: Starling Oncology übertrifft Umsatzprognose für Q2 2026, Aktie legt nachbörslich zu | 10 | Investing.com Deutsch | ||
| 06.08. | The Oncology Institute GAAP EPS of -$0.08 misses by $0.02, revenue of $161.28M beats by $6.08M | 3 | Seeking Alpha | ||
| 06.08. | Starling Oncology, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 03.08. | Oncology Institute, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.08. | The Oncology Institute Rebrands as Starling Oncology | 276 | GlobeNewswire (Europe) | CERRITOS, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI" or "the Company"), one of the largest value-based oncology groups in the United States, announced today that... ► Artikel lesen | |
| 15.07. | Biotech Stocks Hit 52-Week Highs - The Oncology Institute, Inhibikase Therapeutics, Alto Neuroscience, Elevance Health, Privia Health | 1.045 | AFX News | WASHINGTON (dpa-AFX) - These biotech stocks touched a 52-week high on July 14, 2026, attributable to key catalysts like announced offerings to increase capital and the expansion of business... ► Artikel lesen | |
| 09.07. | BTIG hebt Kursziel für The Oncology Institute Aktie nach Umschuldung auf 9 US-Dollar an | 3 | Investing.com Deutsch | ||
| 09.07. | BTIG raises The Oncology Institute stock price target to $9 on debt refinancing | 2 | Investing.com | ||
| 07.07. | Oncology Institute, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.07. | The Oncology Institute Completes Strategic Refinancing with OrbiMed, Repaying the Outstanding $86 Million Deerfield Convertible Note, Strengthening its Balance Sheet, and Improving Liquidity | 1 | GlobeNewswire (USA) |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRIVIA HEALTH GROUP | 24,600 | 0,00 % | Privia Health Group, Inc.: Privia Health Reports Strong Results in the 2025 Performance Year of the Medicare Shared Savings Program | ||
| FRESENIUS MEDICAL CARE | 37,760 | -2,07 % | EQS-News: Fresenius SE & Co. KGaA: Fresenius schließt Verkauf von 13,4 Millionen Aktien der Fresenius Medical Care zu 39,00 Euro je Aktie ab und erzielt rund 524 Millionen Euro | EQS-News: Fresenius SE & Co. KGaA
/ Schlagwort(e): Beteiligung/Unternehmensbeteiligung
Fresenius schließt Verkauf von 13,4 Millionen Aktien der Fresenius Medical Care zu 39,00... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 43,960 | +0,27 % | Aktie zieht an!: Siemens liefert und legt nach, die Strategie überzeugt wirft Fragen auf | © Foto: Joko - JokoSiemens meldet Rekordzahlen und hebt die Mittelfristziele an. Anleger bleiben trotzdem skeptisch, denn die neue Konzernstrategie gilt vielen noch als zu unscharf Enthaltene Werte:... ► Artikel lesen | |
| BILLIONTOONE | 91,50 | -6,15 % | BillionToOne weist Vorwürfe aus Leerverkäufer-Bericht zurück | ||
| BRIGHTSPRING HEALTH SERVICES | 68,35 | 0,00 % | BMO raises BrightSpring Health stock price target on LDD momentum | ||
| GENEDX | 52,19 | 0,00 % | GeneDx Taps Everett Cunningham as CEO | ||
| LIFESTANCE HEALTH GROUP | 13,785 | +0,11 % | LifeStance Health Group, Inc.: LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook | SCOTTSDALE, Ariz., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 6,735 | 0,00 % | Alignment Healthcare falls 9% amid weakness in Medicare Advantage stocks | ||
| HEARTFLOW | 45,905 | +0,03 % | Heartflow stock tumbles despite strong growth beating Q3 expectations | ||
| ARDENT HEALTH | 14,370 | -0,14 % | Ardent Health Stock Falls 20% After Secondary Offering Price Set | ||
| FRESENIUS | 52,66 | -1,44 % | Fresenius: Was hinter dem neuen ADC-Deal steckt | ||
| PROCEPT BIOROBOTICS | 25,190 | 0,00 % | Procept BioRobotics outlines $390M-$410M 2026 revenue, while targeting positive adjusted EBITDA in Q4 | ||
| AVEANNA HEALTHCARE | 10,840 | 0,00 % | RBC Capital reiterates Aveanna Healthcare stock rating at Outperform | ||
| AGILON HEALTH | 90,61 | 0,00 % | Bernstein raises agilon health stock price target on higher EBITDA | ||
| PROGYNY | 36,140 | 0,00 % | Rekorde bei Familienplanung: Progyny glänzt mit blitzsauberer Bilanz und massiven Rückkäufen | Hier an der Wall Street in New York wird oft das schnelle Geld gesucht. Doch die wahren Börsenperlen findet man häufig in lukrativen Nischen, in denen ein Unternehmen zum unverzichtbaren Marktführer... ► Artikel lesen |